Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.

@article{Appelberg2001PatientsWS,
  title={Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.},
  author={Bj{\"o}rn Appelberg and Erkka Syv{\"a}lahti and Tuula Koskinen and O P Mehtonen and Timo T. Muhonen and Hannu H Naukkarinen},
  journal={The Journal of clinical psychiatry},
  year={2001},
  volume={62 6},
  pages={448-52}
}
BACKGROUND Although case reports and open studies have reported augmentation with buspirone to be beneficial in the treatment of depression refractory to treatment with a selective serotonin reuptake inhibitor (SSRI), a recently published randomized, placebo-controlled, double-blind study failed to show superiority of buspirone over placebo in this respect. METHOD One hundred two outpatients who fulfilled DSM-IV criteria for a major depressive episode and who had failed to respond to a… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
One hundred two outpatients who fulfilled DSM - IV criteria for a major depressive episode and who had failed to respond to a minimum of 6 weeks of treatment with either fluoxetine or citalopram were included in this double - blind , randomized , placebo - controlled study .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
One hundred two outpatients who fulfilled DSM - IV criteria for a major depressive episode and who had failed to respond to a minimum of 6 weeks of treatment with either fluoxetine or citalopram were included in this double - blind , randomized , placebo - controlled study .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
Although case reports and open studies have reported augmentation with buspirone to be beneficial in the treatment of depression refractory to treatment with a selective serotonin reuptake inhibitor ( SSRI ) , a recently published randomized , placebo - controlled , double - blind study failed to show superiority of buspirone over placebo in this respect .
Although case reports and open studies have reported augmentation with buspirone to be beneficial in the treatment of depression refractory to treatment with a selective serotonin reuptake inhibitor ( SSRI ) , a recently published randomized , placebo - controlled , double - blind study failed to show superiority of buspirone over placebo in this respect .
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors : results from a placebo - controlled , randomized , double - blind , placebo wash - in study .
Patients with severe depressive symptoms may benefit from augmentation with buspirone .
One hundred two outpatients who fulfilled DSM - IV criteria for a major depressive episode and who had failed to respond to a minimum of 6 weeks of treatment with either fluoxetine or citalopram were included in this double - blind , randomized , placebo - controlled study .
One hundred two outpatients who fulfilled DSM - IV criteria for a major depressive episode and who had failed to respond to a minimum of 6 weeks of treatment with either fluoxetine or citalopram were included in this double - blind , randomized , placebo - controlled study .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
It can not be excluded that augmentation with buspirone may speed up the antidepressive response of patients refractory to treatment with fluoxetine or citalopram .
All Topics